The UK Court held that three of Cephalon’s patents relating to the drug modafinil, used to treat sleep disorders such as narcolepsy, were not infringed and were invalid for lack of inventive step. Click here for the full text of this case. A full summary of this case has been published on Kluwer IP Law.
The Court of Appeal discusses and builds on its previous case law on patentability regarding the issue of whether the subject matter is considered a technical invention. The Court emphasizes that it is sufficient if only part of the patented teaching concerns a technical problem. However, as the next step it has to be determined…
A method claim comprising a step of “providing a donor flow channel for conveying fluid to and from a donor” was found to be excluded from patentability as treatment by surgery and therapy. The Board derived from the description that this step required performing venipuncture and found that venipuncture required professional medical expertise to be…
Faced with a claim directed at a method for determining airway pressure levels, the Board isolated a step from the claim that required changing the airway pressure of an artificial ventilator to observe certain responses. The Board found that this step could not be distinguished from what a medical doctor would do in order to…
If a supplementary protection certificate (SPC) should have been denied (or granted with limited scope), because the six month application period following the date of first marketing approval has lapsed, it is entirely or partially void. There is a lack of legal interest for a negative declaratory action directed at declaring the non-existence of claims…
The Court of Appeal Duesseldorf held that, provided that the alleged infringer proves a legitimate interest in confidentiality, the presentation of the expert opinion to the patentee itself depends on whether the inspection confirms infringement. If the expert opinion confirms infringement, and if the court has no expertise in the relevant technical field, it may…
The board refused to find a set of claims filed with the grounds of appeal admissible, because it concluded from the circumstances that the proprietor had deliberately refused to file these claims during first instance proceedings. The intention of Article 12(4) of the rules of procedure of the EPO boards of appeal was found by…
Hungarian Supreme Court’s decision on conditions for granting supplementary protection certificates (SPC) under the transitional provisions of the Accession Treaty. The Supreme Court held that the first marketing authorization for the pharmaceutical product granted in any EU Member State (including the entire territory of the EU as enlarged due to the 2004 accessions, not restricted…
The Court, in infringement proceedings brought by Novartis against Actavis for marketing generic Valsartan, held that the assessment of infringement had to be made as of the time of infringement, not as of the priority date. This is the first decision in years in Norway taking a position on this issue. The judgement also deals…
The Borgarting Court of Appeal overturned the district court decision which revoked the patents in suit for lack of inventive step. The Court held that even if oxycodone had been known and used to treat pain as an alternative to morphine, the skilled person could not have predicted that a controlled release formulation with oxycodone…
